These findings elucidate how the modulation of IgE may correlate with the overall reduction in allergic symptoms, particularly in patients with concomitant allergies, further supporting the therapeutic role of dupilumab in addressing type 2 inflammation beyond asthma and atopic dermatitis [24,25,26,27,28]. This evidence concerns the gene IGHE and atopic eczema.